- Home
- RCKT
as 06-20-2025 4:00pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 326.4M | IPO Year: | N/A |
| Target Price: | $18.50 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $26.98 | Next Earning Date: | 08-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
Barrons.com
a day ago
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
Barrons.com
3 days ago
Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
MT Newswires
5 days ago
UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating
MT Newswires
23 days ago
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target
MT Newswires
24 days ago
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44
Insider Monkey
24 days ago
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Benzinga
24 days ago
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Insider Monkey
24 days ago
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.